Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y, Quan Y, Wainberg MA.

J Virol. 2012 Dec;86(23):12983-90. doi: 10.1128/JVI.02005-12. Epub 2012 Sep 19.

2.

Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA.

J Virol. 2012 Aug;86(16):8422-31. doi: 10.1128/JVI.00271-12. Epub 2012 May 23.

3.

Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.

Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C.

AIDS. 2013 Mar 27;27(6):879-87. doi: 10.1097/QAD.0b013e32835d9f6d.

PMID:
23262501
4.

Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.

Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni Td, Tremblay CL.

Antimicrob Agents Chemother. 2011 Feb;55(2):600-7. doi: 10.1128/AAC.01192-10. Epub 2010 Dec 6.

5.

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA.

J Virol. 2011 Nov;85(21):11300-8. doi: 10.1128/JVI.05584-11. Epub 2011 Aug 17.

6.

The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA.

J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.

7.

Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA.

Antimicrob Agents Chemother. 2013 Jul;57(7):3100-9. doi: 10.1128/AAC.00348-13. Epub 2013 Apr 22.

8.

Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.

Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, Petropoulos CJ, Wainberg MA.

Antimicrob Agents Chemother. 2013 Nov;57(11):5649-57. doi: 10.1128/AAC.01536-13. Epub 2013 Sep 3.

9.

Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.

Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA.

Antimicrob Agents Chemother. 2009 Nov;53(11):4667-72. doi: 10.1128/AAC.00800-09. Epub 2009 Aug 24.

11.

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.

PMID:
21997204
12.

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2010 Feb;54(2):728-33. doi: 10.1128/AAC.01335-09. Epub 2009 Dec 14.

13.

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.

Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Pérez-Elías MJ, Aguilera A, Caballero E, Soriano V, de Mendoza C; Resistance Platform of the Spanish AIDS Research Network.

AIDS. 2013 Jan 2;27(1):81-5. doi: 10.1097/QAD.0b013e3283584500.

PMID:
22842995
14.

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9.

15.

Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.

Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA.

J Antimicrob Chemother. 2010 Nov;65(11):2291-9. doi: 10.1093/jac/dkq338. Epub 2010 Sep 18.

PMID:
20852269
16.

The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.

Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2401-8. doi: 10.1128/AAC.01795-09. Epub 2010 Mar 22.

17.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

18.

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD.

Antimicrob Agents Chemother. 2010 Nov;54(11):4812-24. doi: 10.1128/AAC.00829-10. Epub 2010 Aug 30.

19.

Biochemical mechanism of HIV-1 resistance to rilpivirine.

Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, Sarafianos SG.

J Biol Chem. 2012 Nov 2;287(45):38110-23. doi: 10.1074/jbc.M112.398180. Epub 2012 Sep 6.

20.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527

Supplemental Content

Support Center